SCHEMBL5263301

SCHEMBL5263301

Cc1ccc(NS(=O)(=O)c2ccc(Cl)cc2)cc1NN1C=C(c2ccncn2)C=CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.40
HTT P42858 1/20 0.39
ALDH1A1 P00352 3/20 0.39
GPR119 Q8TDV5 1/20 0.37
KIT P10721 2/20 0.37
MAPT P10636 4/20 0.36
TNNI3K Q59H18 1/20 0.36
GAA P10253 2/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
CYP2C19 P33261 1/20 0.36
DRD3 P35462 1/20 0.36
HTR6 P50406 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6041141 0.74 KIT (0.51) CYP17A1ALDH1A1KITTNNI3K
SCHEMBL1265232 0.73 TEK (0.55) CYP17A1ALDH1A1GPR119KITMAPT
SCHEMBL4904242 0.68 KIT (0.56) ALDH1A1KIT
SCHEMBL1264582 0.64 TEK (0.62) CYP17A1HTTALDH1A1SMN1; SMN2
SCHEMBL4892544 0.64 KIT (0.69) KIT
SCHEMBL17174222 0.63 CES1 (0.66) ALDH1A1MAPTGAAKMT2AMEN1
SCHEMBL2118369 0.61 ALDH1A1 (0.56) HTTALDH1A1MAPTCYP3A4CYP2D6
SCHEMBL7175892 0.61 CES1 (0.62) ALDH1A1MAPTGAATP53SMN1; SMN2
SCHEMBL526786 0.61 CYP17A1 (0.59) CYP17A1HTTALDH1A1KITMAPT
SCHEMBL3064389 0.59 CES1 (0.54) CYP17A1ALDH1A1KITMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751136-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2007-02-14 EP disclosed
WO-2005113494-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2005-12-01 WO disclosed